Abby Hardy, Author at BioTuesdays

Developments

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Charlotte’s Web (TSX:CWEB; OTC:CWBHF) donated $1-million (US) worth of CBD product to individuals who rely on the company’s products and may be struggling financially as a result of the COVID-19 pandemic. The...

April 21, 2020

Feature

Clarigent Health using AI, machine learning for early detection of potential mental health crises

Closely-held Clarigent is developing a tool to support the early detection of mental health issues, with a goal of preventing suicide in at-risk children and adolescents. “The suicide rate, especially among school-aged...

April 21, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

CytoSorbents gets FDA breakthrough therapy designation for CytoSorb

The FDA granted breakthrough therapy designation to CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of ticagrelor during emergency surgery. Ticagrelor is an antiplatelet drug...

April 20, 2020

Developments

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

The European Medicines Agency granted Mustang Bio’s (NASDAQ:MBIO) MB-107 with advanced therapy medicinal product classification for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked...

April 20, 2020

Developments

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) enrolled the first patient in its Phase 3 trial assessing tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection. The study will enroll...

April 15, 2020

Developments

FDA approves Urogen Pharma’s urothelial cancer drug

The FDA approved UroGen Pharma’s (NASDAQ:URGN) mitomycin gel for the treatment of low-grade upper tract urothelial cancer (UTUC). The gel, which will be marketed under the brand name Jelmyto, inhibits DNA transcription...

April 15, 2020

Developments

Chembio gets FDA emergency use authorization for serological COVID-19 test

The FDA granted emergency use authorization to Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) COVID-19 system. The system is a serological point-of-care test and analyzer that provides numerical readings...

April 15, 2020

Executive Moves

TerrAscend appoints Jason Ackerman as permanent CEO; CFO to step down

Jason Ackerman TerrAscend (OTCQX:TRSSF) appointed Jason Ackerman as CEO and reported that its CFO, Adam Kozak, will step down as the company relocates its financial operations from Toronto to New York City. Mr. Ackerman...

April 14, 2020

Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Tom Civik Five Prime Therapeutics (NASDAQ:FPRX) appointed Tom Civik as president, CEO and a director. William Ringo, who served as Five Prime’s chairman and interim CEO since September 2019, will step down as CEO and...

April 14, 2020

Author - Abby Hardy

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Clarigent Health using AI, machine learning for early detection of potential mental health crises

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

CytoSorbents gets FDA breakthrough therapy designation for CytoSorb

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

FDA approves Urogen Pharma’s urothelial cancer drug

Chembio gets FDA emergency use authorization for serological COVID-19 test

TerrAscend appoints Jason Ackerman as permanent CEO; CFO to step down

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Subscribe